Although randomized clinical trials are the gold standard for providing the data to support new drug approvals, the commonly short duration and restrictive entry criteria of these trials generally result in important data gaps at the time of new drug introduction.
Evaluating “Real World Data” collected during the course of usual care can be utilized to provide “Real World Evidence” concerning the efficacy of the drug in the wide group of eligible patients, as well long-term safety data.
Pfizer fully embraces the importance of generating reliable, insightful, and transparent RWE based on high-quality, fit-for-purpose RWD. We provide support for multiple types of RWE studies, and welcome your interest to discuss further.
The Real World Evidence team:
